Company news
Vertex Pharmaceuticals Incorporated news in 2006
Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2006, newest first.
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
August 3, 2006
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual Canaccord Adams Summer Seminar
August 2, 2006
Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results
July 26, 2006
Vertex Pharmaceuticals Announces the Date of its Second Quarter 2006 Financial Results Conference Call and Webcast
July 6, 2006
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
June 30, 2006
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
June 30, 2006
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
June 16, 2006
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences
June 9, 2006
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naive HCV Patients
May 23, 2006
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
May 22, 2006
Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis
May 17, 2006
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
May 16, 2006
Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
May 11, 2006
Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients
April 29, 2006
New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950
April 26, 2006
Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
April 25, 2006
Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
April 5, 2006
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF
March 23, 2006
Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis
March 8, 2006
Vertex Pharmaceuticals Reports 2005 Financial Results
February 7, 2006
Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program
February 7, 2006
VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon
January 9, 2006
Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
January 9, 2006